Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F20%3A10419563" target="_blank" >RIV/00216208:11150/20:10419563 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/20:10419563

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=_J0Wpo6Jac" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=_J0Wpo6Jac</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/1751-2980.12927" target="_blank" >10.1111/1751-2980.12927</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease

Popis výsledku v původním jazyce

Objectives Over the past few years, mucosal healing (MH) has emerged as a promising goal in the treatment of pediatric patients with Crohn&apos;s disease (CD). We aimed to assess whether combination therapy with infliximab (IFX) + azathioprine (AZA) was more effective than AZA therapy alone in achieving mucosal healing in pediatric patients with CD. Methods Newly diagnosed pediatric patients with CD at the Department of Pediatrics in University Hospital in Hradec Kralove were retrospectively recruited (2000-2014). The patients were divided into two groups according to the therapy: (a) IFX + AZA +/- corticosteroids +/- 5-aminosalicylic acid (5-ASA) (n = 16); and (b) AZA +/- corticosteroids +/- 5-ASA (n = 40). The patients were also divided into two groups: &quot;MH&quot; and &quot;no MH,&quot; according to their MH status. MH was defined as the complete endoscopic disappearance of all mucosal ulcerations (including aphthous ulcerations) and the absence of any sign of mucosal inflammation in the terminal ileum and the large bowel. Results Of 56 patients, MH was observed in 56% (9/16) treated with combined therapy in comparison with 15% (6/40) of patients in the AZA group (P = 0.006). The median dose of AZA in both groups was 2.1 mg/kg per day. We observed eight adverse events in seven patients from the IFX + AZA group. Adverse effects were less common in the AZA group (P = 0.002). Conclusion Combined therapy (IFX + AZA) was more effective in achieving MH in pediatric CD than treatment with AZA alone.

Název v anglickém jazyce

Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease

Popis výsledku anglicky

Objectives Over the past few years, mucosal healing (MH) has emerged as a promising goal in the treatment of pediatric patients with Crohn&apos;s disease (CD). We aimed to assess whether combination therapy with infliximab (IFX) + azathioprine (AZA) was more effective than AZA therapy alone in achieving mucosal healing in pediatric patients with CD. Methods Newly diagnosed pediatric patients with CD at the Department of Pediatrics in University Hospital in Hradec Kralove were retrospectively recruited (2000-2014). The patients were divided into two groups according to the therapy: (a) IFX + AZA +/- corticosteroids +/- 5-aminosalicylic acid (5-ASA) (n = 16); and (b) AZA +/- corticosteroids +/- 5-ASA (n = 40). The patients were also divided into two groups: &quot;MH&quot; and &quot;no MH,&quot; according to their MH status. MH was defined as the complete endoscopic disappearance of all mucosal ulcerations (including aphthous ulcerations) and the absence of any sign of mucosal inflammation in the terminal ileum and the large bowel. Results Of 56 patients, MH was observed in 56% (9/16) treated with combined therapy in comparison with 15% (6/40) of patients in the AZA group (P = 0.006). The median dose of AZA in both groups was 2.1 mg/kg per day. We observed eight adverse events in seven patients from the IFX + AZA group. Adverse effects were less common in the AZA group (P = 0.002). Conclusion Combined therapy (IFX + AZA) was more effective in achieving MH in pediatric CD than treatment with AZA alone.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Digestive Diseases

ISSN

1751-2972

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

CN - Čínská lidová republika

Počet stran výsledku

6

Strana od-do

705-710

Kód UT WoS článku

000594995500004

EID výsledku v databázi Scopus

2-s2.0-85097054205